Hasil Pencarian  ::  Simpan CSV :: Kembali

"Unit Stroke (US) telah terbukti sangat baik dalam peawatan pasien stroke.Penelitian US pada tahitn 1990 menunjukkan hasil dengan peningkatan rata-rata kehidupan dan perbaikan status fungsionai pendetita dun menurunkan hari perawatan pasien, Di Indonesia US masih bum sehingga penelitian tentang tatalaksana perawatan dl US sangat diperlukan.Penelitian ini dilakukan untuk evaluasi manfaat US sebagai perawatan pasien stroke khususnya perbaikan status fungsional pasien dibandingkan perawatan pasien di Sudut Stroke Bangsal Umum Neurologi. Hasil penelitian menunjukan perbaikan status fungsionai stroke (Skor NIHSS) baik di US maupiin di Sudut Stroke Bangsal Neurologi Umum.Data memperlihatkan penumnan nilai NIHSS yaitu 17,35 tnenjadi 5,31 sedangkan di Sudut stroke 13,83 menjadi 8,87. Dengan menggunakan Independent t-test,penurunan NIHSS di US signifikan dibandingkan sudut stroke di bangsal neurologi umum. (MedJ Indones 2006; 15:30-3).

---

Stroke unit has been believed us the best institutional care for stroke patients. Recent researches in 1990s indicated thai stroke units can produce increasing survival rate and improving the functional state of the patients which can reduce the need for institutional care after stroke. In Indonesia, stroke unit is still new. Because stroke unit has educational role beside its clinical importance, the research about stroke unit especially in its value in managing stroke patients in Indonesia is needed.

This study was evaluated the effectiveness of stroke unit care in managing stroke patients especially in improving the functional state of the patients in compared with conventional care of stroke corner in general neurology ward. This study indicated that both stroke unit (SU) and stroke corner in general neurology ward (SC) shows reduction in NIHSS score. In Stoke Unit, the reduction of NIHSS was 17.35 to 5.31 while in Neurology ward from 13.83 to 8.87. Using independent t-test, the reduction of NIHSS in stroke unit is more significance compared with stroke corner in general neurology ward (p=0,000). (Med J Indones 2006; 15:30-3)."

"Penelitian ini bertujuan menilai efektivitas dan keamanan Acetylcholinesterase Inhibitor Galantamine pada penderita Alzheimer dan Alzheimer?s Disease (AD) yang disertai dengan penyakit serebrovaskular (AD+CVD atau Mixed Dementia). Galantamine diberikan selama 6 bulan pada 28 penderita AD dan AD + CVD. Evaluasi kognitif dilakukan dengan menggunakan Mini Mental State Examination (MMSE), Restricted Reminding (RR), Neuropsycholgy Assessment, evaluasi fungsi global dengan Clinical Dementia Rating (CDR), evaluasi perubahan perilaku dengan Neuropsychiatric Inventory (NPI). Hasil penelitian pada 28 penderita AD dan AD + CVD, Galantamine memberikan perbaikan fungsi kognitif yang bermakna secara klinis maupun statistik setelah terapi 6 bulan dibandingkan data dasar awal (skor MMSE p<0.05, skor RR p<0.05, NA p<0.05), perbaikan fungsi global (CDR p<0.05) dan perbaikan gejala perilaku (NPI p<0.05). Efek samping ringan (32%) mual-mual dan anokresia terjadi saat titrasi dosis obat dan dapat diatasi dengan domperidone. Disimpulkan bahwa Galantamine efektif memberikan perbaikan fungsi kognitif, fungsi global, gejala perilaku dan aman serta dapat ditoleransi dengan baik. (Med J Indones 2007; 16:94-100).

---

This study was aimed to evaluate the efficacy and safety of Acetylcholinesterase Inhibitor Galantamine (Reminyl®) for patients with Alzheimer?s Disease (AD) and Alzheimer?s Disease with cerebrovascular Disease (AD+CVD or mixed Dementia). A 6-month open label observational study of Galantamine has been conducted on 28 patients with AD and AD+CVD patients. Primary endpoints were cognitive performance as assessed using the Mini Mental Scale Examination (MMSE), the Restricted Reminding Test), the Neuropsychology Assessment, the Clinical Dementia Rating (CDR) to assess global function and the Neuropsychiatric Inventory (NPI) to assess behavioral symptoms. Patients were also monitored for safety evaluation. Six month Galantamine group had a significant better outcome of cognitive performance, global function and behavioral symptoms compared with the baseline data as were assessed using the MMSE (p<0.05), the Restricted Reminding (p<0.05), the Neuropsychology Assessment (p<0.05), the CDR (p<0.05) and the NPI (p<0.05). Minimal adverse events (32%) were anorexia and nausea. It is concluded that Galantamine has a significant benefit to improve cognitive, global function, behavioral symptoms and only caused minimal adverse events. (Med J Indones 2007; 16:94-100)."